Envoy Medical Inc (COCH)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.71-2.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · COCH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 254.7% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -42.3% |
Growth built into the price is above our model estimate.
The price assumes 297.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
COCH — M&A activity — Termination of a Material Definitive Agreement
Dated 2026-06-30
Termination of a Material Definitive Agreement On June 24, 2026, Envoy Medical, Inc. (the “Company”) terminated its At The Market Offering Agreement, dated January 17, 2025 (the “ATM Agreement”). The ATM Agreement was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated January 17, 2025. A copy of a press release issued by the Company on June 24, 2026 regarding termination of the ATM Agreement is attached hereto as Exhibit 99.1. The information set forth Exhibit 99.1 is bei…
Why it matters: The FDA's feedback will be crucial for the timeline of the Acclaim implant's approval.
Watch forThe FDA gives good feedback on the first module of the PMA application.
Also watch forThe FDA asks for more information or slows down the review process.
Why it matters: Good data may help get FDA approval. It could also increase investor trust.
Supportive ifThe first 12-month data shows big improvements in patient outcomes.
Worry ifData shows serious problems or no improvements in key areas.
Why it matters: Cash balance updates will show if the company can keep running during the PMA submission.
Worry ifCash balance remains above $15 million after Q2 2026.
Less concerning ifCash balance falls below $15 million after Q2 2026.
Why it matters: The PMA submission is important for selling the Acclaim cochlear implant.
Supportive ifThe PMA submission is on time. This follows 12-month data from trial patients.
Worry ifThe submission is late because of problems with data collection.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$222 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $810 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,548 loss on $10,000 · 75.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Positive data after 12 months would prove the Acclaim cochlear implant works well.
Supportive ifThe company reports a mean CNC word recognition score of at least 53.2% from the full cohort at the 12-month follow-up.
Worry ifThe mean CNC word recognition score is below 53.2% at the 12-month follow-up.
Why it matters: Increasing losses show problems with cash flow and how well the company runs.
Worry ifOperating losses go over -$6M in the next quarterly report.
Less concerning ifOperating losses drop to below -$6M in the next quarterly report.
Why it matters: Updates on cash runway will show if the company can keep running until PMA submission.
Watch forThe company reports cash reserves of at least $15 million by Q4 2026.
Also watch forThe company reports cash reserves falling below $15 million by Q4 2026.
Why it matters: The second module is now submitted. This shows progress for the Acclaim cochlear implant approval.
Supportive ifThe company submits the second module of the PMA application to the FDA by the end of Q4 2026.
Worry ifThe company delays the submission of the second module beyond Q4 2026.
Why it matters: Updates on the PMA submission will show if Envoy can extend its cash runway. This is crucial for its financial health.
Supportive ifA press release confirming the submission of the PMA to the FDA.
Worry ifNo updates on the PMA submission or delays in the timeline.
Why it matters: A clear timeline for the PMA submission shows progress for the Acclaim cochlear implant.
Supportive ifManagement announces a specific date for the PMA submission to the FDA.
Worry ifThere are more delays in the PMA submission timeline. There are no updates from management.
Why it matters: This submission is important for the planned launch of the Acclaim cochlear implant.
Supportive ifThe company submits the final module of its PMA application to the FDA as planned in Q2 2027.
Worry ifThe company delays the submission of the final module beyond Q2 2027.
Why it matters: Cash levels will show if the company can fund operations and trials after the PMA submission.
Worry ifCash balance remains above $15 million after the PMA submission.
Less concerning ifCash balance drops below $15 million after the PMA submission.
Why it matters: The PMA submission is a key step toward FDA approval and commercialization. It shows progress in the pivotal trial.
Supportive ifThe company submits the PMA application to the FDA by the end of Q3 2026.
Worry ifThe PMA submission is delayed beyond Q4 2026.
Why it matters: A strong cash position is crucial for ongoing clinical trials and operations.
Supportive ifManagement says cash will last past the PMA submission into late 2027.
Worry ifCash is dropping fast, raising worries about paying for future operations.
Why it matters: More patents will help the company compete better in the cochlear implant market.
Supportive ifThe company will get at least two more patents for implantable devices by Q4 2026.
Worry ifThe company fails to secure any new patents by the end of Q4 2026.